Condition: Advanced Hepatocellular Carcinoma · Refractory Hepatocellular Carcinoma · Biliary Tract Cancer · Sponsor: University of Texas Southwestern Medical Center
The goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.
This description comes directly from the study's public registry record.
Carrie Manwaring · 214-648-7097 · Carrie.Manwaring@UTSouthwestern.edu
Always discuss trial participation with your own doctor first.
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06789848